In Prolopa, levodopa is the primary agent that crosses the blood-brain barrier to be converted into dopamine, essential for managing the motor symptoms of Parkinson’s disease. On the other hand, Benserazide blocks the enzyme that breaks down levodopa in the peripheral system (outside the brain), preventing its premature conversion before reaching the brain where it’s needed. This enhances the availability of levodopa for conversion into dopamine, effectively alleviating symptoms of rigidity, tremors, and bradykinesia associated with Parkinson’s disease.